Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone + raltitrexed + anlotinib + benmelstobart
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy is an investigational antineoplastic regimen consisting of four distinct agents: mitoxantrone, raltitrexed, anlotinib, and benmelstobart (TQB2450). Mitoxantrone is a type II topoisomerase inhibitor that induces DNA damage, while raltitrexed is a specific thymidylate synthase inhibitor that disrupts DNA synthesis. Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) that primarily inhibits angiogenesis by targeting VEGFR, FGFR, PDGFR, and c-Kit. Benmelstobart is a humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), designed to restore anti-tumor immune responses. The combination is primarily being evaluated for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and other refractory solid tumors, aiming to leverage the synergistic effects of cytotoxic chemotherapy, anti-angiogenesis, and immune checkpoint blockade.
- Brand names
- Focus V
- Other names
- mitoxantrone + raltitrexed + anlotinib + TQB2450mitoxantrone + raltitrexed + anlotinib + benmelstobartBenmelstobart + Anlotinib + Mitoxantrone + Raltitrexed
02
Targets
TOP2A (DNA topoisomerase II)TS (Thymidylate synthase)PKC (Protein kinase C family)VEGFR2 (Vascular endothelial growth factor receptor 2)CD80 (T-lymphocyte activation antigen CD80)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on mitoxantrone + raltitrexed + anlotinib + benmelstobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone + raltitrexed + anlotinib + benmelstobart.